Management of second ipsilateral breast tumor event: An advocacy for a randomized trial

Cancer Radiother. 2024 Jan 11:S1278-3218(23)00246-9. doi: 10.1016/j.canrad.2023.11.001. Online ahead of print.ABSTRACTFor a second ipsilateral breast tumor event, salvage mastectomy is the standard of care while second conservative treatment is a possible option. However, level 1 proofs are missing, leading to perform salvage mastectomy for patients who could receive second conservative treatment and consequently avoid psychological/quality of life salvage mastectomy deleterious impacts. A phase 3 randomized trial comparing salvage mastectomy to second conservative treatment is needed. Here we discuss what would be to us the optimal design of such trial to confirm the non-inferiority between the two salvage options, with a focus on methodological aspects in terms of patient characteristics and statistical issues.PMID:38216433 | DOI:10.1016/j.canrad.2023.11.001

Source: Cancer Radiotherapie - January 12, 2024 Category: Cancer & Oncology Authors: J-M Hannoun-L évi A Savignoni J-G F éron C Malhaire C Ezzili A Br édart P Loap Y Kirova Source Type: research